ALS United Mid-Atlantic expresses our profound disappointment in the news from Amylyx Pharmaceuticals that Relyvrio did not meet its primary or secondary endpoints in its Phase 3 clinical trial. We remain hopeful that the data from Amylyx will provide useful insight that benefits ALS research and moves us closer to a cure. The current pace of ALS research is very encouraging and we are optimistic that ongoing studies and trials will lead to positive results for the ALS community.
